Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Aducanumab Termination Was Wrenching Decision: Eisai CEO
April 24, 2019
- In Authorized Generic Spree, Daiichi Sankyo Espha Focuses More on “Popularization” than “Sales” When It Comes to Cancer AGs
April 24, 2019
- Teva Takeda to Shutter 2 Factories in Shiga
April 24, 2019
- Boehringer Seeks Additional Indication for Ofev
April 23, 2019
- Nippon Kayaku Grabs Japan Rights to Lilly’s Soon-to-Launch Portrazza
April 23, 2019
- Banned Doping Substance Contamination on API Production Line: Sawai Report
April 23, 2019
- MSD Japan Chief Flags Re-Pricing for Keytruda, Says It’s “Heading into That Range”
April 22, 2019
- SanBio Vows to Create In-House Marketing System in Japan by 2020, Eyes Global Leader by 2025: President
April 22, 2019
- Sumitomo Dainippon Cuts Sales Outlook for FY2018, Ups Profit Forecast
April 22, 2019
- Novartis to Begin Kymriah Treatment at 2-3 Japan Sites, Looks at Gradual Expansion
April 19, 2019
- Boehringer to Remain Major Employer in Japan with As-Needed Staffer Placement
April 19, 2019
- Chugai-Originated Eczema Drug Hits Primary Goal in Japan PIII: Maruho
April 19, 2019
- Pfizer Japan Mulls Over Alternative Manufacturing Route Following Suspension of Methotrexate Production in Germany
April 19, 2019
- SanBio Unveils Positive PII Data for SB623 in Traumatic Brain Injury
April 18, 2019
- Sanofi Pushing Drugs’ Added Values to Secure Patient Access amid Rising Awareness for Economic Efficiency
April 18, 2019
- Bayer, Hokkaido Pref. Join Forces to Tackle Life Style Diseases
April 18, 2019
- Japan Pharma Market Grew 87.1% in 30 Years of Heisei Era: IQVIA
April 18, 2019
- With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year
April 17, 2019
- Evenity Heavily Pitched via In-Clinic Seminars in February: Anterio
April 17, 2019
- Toa Eiyo Grants China Marketing Rights for Bisono Tape to Local Firm
April 17, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…